Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.

European journal of clinical pharmacology - 1 Jun 2010

Puehringer Helene, Loreth Ralph M, Klose Gudrun, Schreyer Brigitte, Krugluger Walter, Schneider Barbara, Oberkanins Christian

Abstract excerpt

PURPOSE: Phenprocoumon, similar to other coumarin-derived anticoagulants, is associated with a large variation in the individual dose requirement to achieve stable anticoagulation. Polymorphisms in the vitamin K epoxide reductase complex subunit 1 (VKORC1) and the liver enzyme cytochrome P450 2C9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Austria

Share to Cytochrome P-450 CYP2C9

Share to Germany

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 20376629
DOI: 10.1007/s00228-010-0809-2

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20376629-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.PMID 20376629Read ↗

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.Semantic proximity Read ↗

Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.Semantic proximity Read ↗

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.Semantic proximity Read ↗

A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms.Semantic proximity Read ↗

VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.Semantic proximity Read ↗

Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.Semantic proximity Read ↗

VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Semantic proximity Read ↗

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.Semantic proximity Read ↗

An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.Semantic proximity Read ↗

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.Semantic proximity Read ↗

Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.Semantic proximity Read ↗

Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.